BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35930599)

  • 21. ER-α36-mediated gastric cancer cell proliferation via the c-Src pathway.
    Wang X; Deng H; Zou F; Fu Z; Chen Y; Wang Z; Liu L
    Oncol Lett; 2013 Aug; 6(2):329-335. PubMed ID: 24137325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance.
    Yin L; Wang ZY
    Steroids; 2016 Jul; 111():95-99. PubMed ID: 26884313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling.
    Kang L; Zhang X; Xie Y; Tu Y; Wang D; Liu Z; Wang ZY
    Mol Endocrinol; 2010 Apr; 24(4):709-21. PubMed ID: 20197310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.
    Pan C; Hu Y; Li J; Wang Z; Huang J; Zhang S; Ding L
    PLoS One; 2014; 9(8):e104459. PubMed ID: 25127034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen-independent effects of ER-α36 in ER-negative breast cancer.
    Zhang J; Li G; Li Z; Yu X; Zheng Y; Jin K; Wang H; Gong Y; Sun X; Teng X; Cao J; Teng L
    Steroids; 2012 May; 77(6):666-73. PubMed ID: 22402113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biphasic ER-α36-mediated estrogen signaling regulates growth of gastric cancer cells.
    Wang X; Huang X; Fu Z; Zou F; Li Y; Wang Z; Liu L
    Int J Oncol; 2014 Dec; 45(6):2325-30. PubMed ID: 25231129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor variant ER-α36 is involved in estrogen neuroprotection against oxidative toxicity.
    Han S; Zhao B; Pan X; Song Z; Liu J; Gong Y; Wang M
    Neuroscience; 2015 Dec; 310():224-41. PubMed ID: 26383254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design.
    Adewumi AT; Mosebi S
    Biomolecules; 2023 Dec; 13(12):. PubMed ID: 38136668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor-α36 is involved in diallyl sulfide-induced inhibition of malignant growth of HepG2 and Huh7 hepatocellular carcinoma cells.
    Wu W; Chen H; Wang R; Chen J; Yu H; Wei Z; Liu X; Xue M; Chen Q; Zhou H; Fu Z
    Environ Toxicol; 2022 Feb; 37(2):270-281. PubMed ID: 34724321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in breast cancer.
    Zhao Y; Deng C; Lu W; Xiao J; Ma D; Guo M; Recker RR; Gatalica Z; Wang Z; Xiao GG
    Mol Med; 2011; 17(11-12):1233-41. PubMed ID: 21826373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel anticancer agent Broussoflavonol B downregulates estrogen receptor (ER)-α36 expression and inhibits growth of ER-negative breast cancer MDA-MB-231 cells.
    Guo M; Wang M; Deng H; Zhang X; Wang ZY
    Eur J Pharmacol; 2013 Aug; 714(1-3):56-64. PubMed ID: 23769740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the understanding of the structure and function of ER-α36,a novel variant of human estrogen receptor-alpha.
    Rao J; Jiang X; Wang Y; Chen B
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):231-7. PubMed ID: 21888973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
    Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY
    PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ER-α36, a novel variant of ERα, is involved in the regulation of Tamoxifen-sensitivity of glioblastoma cells.
    Liu Y; Huang L; Guan X; Li H; Zhang QQ; Han C; Wang YJ; Wang C; Zhang Y; Qu C; Liu J; Zou W
    Steroids; 2016 Jul; 111():127-133. PubMed ID: 26898538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling.
    Wang Z; Zhang X; Shen P; Loggie BW; Chang Y; Deuel TF
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9063-8. PubMed ID: 16754886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Egloff AM; Rothstein ME; Seethala R; Siegfried JM; Grandis JR; Stabile LP
    Clin Cancer Res; 2009 Nov; 15(21):6529-40. PubMed ID: 19825947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of estrogen receptor-α36 expression attenuates metastasis of hepatocellular carcinoma cells.
    Wang R; Chen J; Yu H; Wei Z; Ma M; Ye X; Wu W; Chen H; Fu Z
    Environ Toxicol; 2022 May; 37(5):1113-1123. PubMed ID: 35044086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrogen Receptor (ER)-α36 Is Involved in Estrogen- and Tamoxifen-Induced Neuroprotective Effects in Ischemic Stroke Models.
    Zou W; Fang C; Ji X; Liang X; Liu Y; Han C; Huang L; Zhang Q; Li H; Zhang Y; Liu J; Liu J
    PLoS One; 2015; 10(10):e0140660. PubMed ID: 26484775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.